| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2013-06-13 | protease inhibitor BI 201335 (faldaprevir) and polymerase inhibitor BI 207127 (deleobuvir) | hepatitis C |
2b | Boehringer Ingelheim (Germany) | Infectious diseases |
| 2013-06-13 | GLPG0634 | rheumatoid arthritis |
2a | Galapagos (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2013-06-12 | laquinimod | active lupus nephritis | 2a | Active Biotech (Sweden) Teva Pharmaceuticals (Israel) | Autoimmune diseases |
| 2013-06-12 | brodalumab | 2 | Amgen (USA) AstraZeneca (UK) | Autoimmune diseases | |
| 2013-06-12 | ALX-0061 | rheumatoid arthritis | 1-2 | Ablynx (Belgium) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2013-06-11 | teprotumumab (RG1507) | active thyroid eye disease | 2 | Genmab (Denmark) River Vision Development Corporation (USA) | Ophtalmological diseases |
| 2013-06-11 | aldesleukin | type 1 diabetes | Addenbrooke\'s Hospital (UK) Cambridge Institute for Medical Research (CIMR) | Metabolic diseases | |
| 2013-06-06 | Eylea® (VEGF Trap-Eye - aflibercept ophthalmic solution) | myopic choroidal neovascularization (mCNV) |
3 | Bayer Healthcare (Germany) Regeneron Pharmaceuticals (USA) | Ophtalmological diseases |
| 2013-06-06 | simeprevir (TMC435) | patients with genotype 1 hepatitis C | 3 | Medivir (Sweden) Janssen Pharmaceuticals (J&J - USA) | Infectious diseases |
| 2013-06-05 | ozenoxacin | impetigo |
3 | Ferrer (Spain) | Infectious diseases - Dermatological diseases |
| 2013-06-04 | fostamatinib | rheumatoid arthritis | 3 | AstraZeneca (UK) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2013-06-03 | tasquinimod | prostate cancer |
2 | Active Biotech (Sweden) Ipsen (France) | Cancer - Oncology |
| 2013-06-03 | NUC-1031 | advanced and progressing solid tumors | 1 | NuCana BioMed (UK) | Cancer - Oncology |
| 2013-06-03 | nintedanib | non-small cell lung cancer (NSCLC) | 3 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
| 2013-06-03 | GDC-0199/ABT-199, also known as RG7601 | chronic lymphocytic leukemia |
1 | Roche (Switzerland) AbbVie (USA -IL) | Cancer - Oncology |
| 2013-05-31 | AZD3965 | 1 | Cancer Research UK (UK) | Cancer - Oncology | |
| 2013-05-31 | Seprehvir® (HSV1716) | sarcomas, such as rhabdomyosarcoma, osteosarcoma and Ewing sarcoma | 1 | Virttu Biologics (UK) | Cancer - Oncology |
| 2013-05-31 | True Human™ therapeutic antibody neutralizing interleukin-6 (IL-6) | XBiotech (USA - TX) | Cancer - Oncology | ||
| 2013-05-29 | CV301 (CEA/MUC-1/TRICOM) | metastatic colorectal cancer | 2 | Bavarian Nordic (Denmark) | Cancer - Oncology |
| 2013-05-29 | ofatumumab (Arzerra®) | chronic lymphocytic leukemia |
3 | Genmab (Denmark) GSK (UK) | Cancer - Oncology |
